Combination immunotherapy and chemotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) with standard chemotherapy (gemcitabine and cisplatin) for a rare type of liver cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of combined hepatocellular-cholangiocarcinoma that is advanced or has spread.
- You must have at least one tumor that can be measured on scans.
- You must be able to perform daily activities with minimal help (ECOG score 0 or 1).
- Your liver, kidney, and blood cell counts must be within acceptable levels.
- You must not have had certain prior treatments for advanced disease, including gemcitabine, cisplatin, or certain immunotherapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with a rare and advanced liver cancer called combined hepatocellular cholangiocarcinoma (CHC). Doctors will use information from your tumor and health history to find the best treatment approach for your specific cancer type.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a combination of two drugs, cadonilimab and capecitabine, given after surgery to remove a rare type of liver cancer that has both hepatocellular and cholangiocarcinoma features. The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a combination of treatments for liver cancer that cannot be removed with surgery. It combines a procedure called TACE, which delivers chemo directly to the tumor, with drugs that boost your immune system and block cancer growth. This might help shrink tumors and slow the cancer.
Hear when a new Combined Hepatocellular and Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.